CN1958608B - 抗禽流感特异性IgY的制备方法及其制剂 - Google Patents
抗禽流感特异性IgY的制备方法及其制剂 Download PDFInfo
- Publication number
- CN1958608B CN1958608B CN2005101168462A CN200510116846A CN1958608B CN 1958608 B CN1958608 B CN 1958608B CN 2005101168462 A CN2005101168462 A CN 2005101168462A CN 200510116846 A CN200510116846 A CN 200510116846A CN 1958608 B CN1958608 B CN 1958608B
- Authority
- CN
- China
- Prior art keywords
- igy
- influenza
- virus
- specificity
- birds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 122
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 206010022000 influenza Diseases 0.000 title claims description 84
- 206010064097 avian influenza Diseases 0.000 claims abstract description 199
- 241000700605 Viruses Species 0.000 claims abstract description 136
- 239000000427 antigen Substances 0.000 claims abstract description 95
- 108091007433 antigens Proteins 0.000 claims abstract description 92
- 102000036639 antigens Human genes 0.000 claims abstract description 89
- 208000015181 infectious disease Diseases 0.000 claims abstract description 79
- 208000003322 Coinfection Diseases 0.000 claims abstract description 76
- 235000013601 eggs Nutrition 0.000 claims abstract description 54
- 239000000287 crude extract Substances 0.000 claims abstract description 36
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 26
- 238000001914 filtration Methods 0.000 claims abstract description 25
- 239000002131 composite material Substances 0.000 claims abstract description 24
- 102000018265 Virus Receptors Human genes 0.000 claims abstract description 23
- 108010066342 Virus Receptors Proteins 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 8
- 241000712461 unidentified influenza virus Species 0.000 claims description 125
- 208000002979 Influenza in Birds Diseases 0.000 claims description 89
- 241000894006 Bacteria Species 0.000 claims description 69
- 239000007788 liquid Substances 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 230000036039 immunity Effects 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 35
- 239000006228 supernatant Substances 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 32
- 244000052616 bacterial pathogen Species 0.000 claims description 30
- 238000002347 injection Methods 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 26
- 239000002671 adjuvant Substances 0.000 claims description 24
- 238000004440 column chromatography Methods 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 102000002322 Egg Proteins Human genes 0.000 claims description 17
- 108010000912 Egg Proteins Proteins 0.000 claims description 17
- 239000007762 w/o emulsion Substances 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 11
- 239000002953 phosphate buffered saline Substances 0.000 claims description 11
- 238000005507 spraying Methods 0.000 claims description 11
- 238000012546 transfer Methods 0.000 claims description 10
- 230000003211 malignant effect Effects 0.000 claims description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 8
- 238000005227 gel permeation chromatography Methods 0.000 claims description 8
- 238000005374 membrane filtration Methods 0.000 claims description 8
- 235000010413 sodium alginate Nutrition 0.000 claims description 8
- 239000000661 sodium alginate Substances 0.000 claims description 8
- 229940005550 sodium alginate Drugs 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 241000606768 Haemophilus influenzae Species 0.000 claims description 7
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 7
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims description 7
- 241000194017 Streptococcus Species 0.000 claims description 6
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 6
- 239000006189 buccal tablet Substances 0.000 claims description 6
- 229940046011 buccal tablet Drugs 0.000 claims description 6
- 230000002949 hemolytic effect Effects 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 239000003380 propellant Substances 0.000 claims description 6
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 6
- 241000204031 Mycoplasma Species 0.000 claims description 5
- 241000607142 Salmonella Species 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 5
- 229940012356 eye drops Drugs 0.000 claims description 5
- 239000007923 nasal drop Substances 0.000 claims description 5
- 239000007922 nasal spray Substances 0.000 claims description 5
- 229940097496 nasal spray Drugs 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000013345 egg yolk Nutrition 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 3
- 241000204003 Mycoplasmatales Species 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 10
- 230000003053 immunization Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 244000052769 pathogen Species 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 101710154606 Hemagglutinin Proteins 0.000 description 62
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 62
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 62
- 101710176177 Protein A56 Proteins 0.000 description 62
- 239000000185 hemagglutinin Substances 0.000 description 61
- 241000271566 Aves Species 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 238000005336 cracking Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 229960003971 influenza vaccine Drugs 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 241000272534 Struthio camelus Species 0.000 description 18
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 16
- 239000004141 Sodium laurylsulphate Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 16
- 241000272814 Anser sp. Species 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 238000012216 screening Methods 0.000 description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 14
- 238000001976 enzyme digestion Methods 0.000 description 14
- 239000007921 spray Substances 0.000 description 14
- 241000287828 Gallus gallus Species 0.000 description 13
- 210000001643 allantois Anatomy 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 12
- 210000003837 chick embryo Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- 241000272525 Anas platyrhynchos Species 0.000 description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 241000235058 Komagataella pastoris Species 0.000 description 7
- 241000235648 Pichia Species 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 7
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 235000014103 egg white Nutrition 0.000 description 7
- 210000000969 egg white Anatomy 0.000 description 7
- 230000005611 electricity Effects 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 230000031700 light absorption Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- 238000007873 sieving Methods 0.000 description 7
- 102000005348 Neuraminidase Human genes 0.000 description 6
- 108010006232 Neuraminidase Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003278 egg shell Anatomy 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 238000000197 pyrolysis Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 210000001136 chorion Anatomy 0.000 description 4
- 230000000249 desinfective effect Effects 0.000 description 4
- 238000001641 gel filtration chromatography Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 239000003456 ion exchange resin Substances 0.000 description 4
- 229920003303 ion-exchange polymer Polymers 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000207199 Citrus Species 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000020971 citrus fruits Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000000071 ovigerm Anatomy 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000998 shell membrane Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000011100 viral filtration Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000272808 Anser Species 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 101000714457 Chaetoceros protobacilladnavirus 2 Capsid protein Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 241000611306 Taeniopygia guttata Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000005262 decarbonization Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
IgY | 抗原 | 抗体结合效价 |
抗禽流感病毒鸭IgY | H5N1禽流感病毒 | 1∶2,048 |
IgY纯品 | 纯IgY含量 |
抗禽流感特异性IgY | 99.99% |
抗继发感染细菌的特异性IgY | 99.99% |
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101168462A CN1958608B (zh) | 2005-10-31 | 2005-10-31 | 抗禽流感特异性IgY的制备方法及其制剂 |
PCT/CN2006/000212 WO2007068154A1 (en) | 2005-10-31 | 2006-02-13 | A method for preparing specific igy against mutant avian influenza virus and the preparation tηereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101168462A CN1958608B (zh) | 2005-10-31 | 2005-10-31 | 抗禽流感特异性IgY的制备方法及其制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1958608A CN1958608A (zh) | 2007-05-09 |
CN1958608B true CN1958608B (zh) | 2012-07-04 |
Family
ID=38070473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005101168462A Active CN1958608B (zh) | 2005-10-31 | 2005-10-31 | 抗禽流感特异性IgY的制备方法及其制剂 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1958608B (zh) |
WO (1) | WO2007068154A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9701737B2 (en) | 2003-02-19 | 2017-07-11 | Camas, Incorporated | Immunogen adherence and method of making and using same |
MX2012012915A (es) * | 2010-05-07 | 2013-05-06 | Camas Inc | Adherencia de inmunogeno y metodo para formar y utilizar el mismo. |
CN102526727B (zh) * | 2012-01-04 | 2014-05-07 | 河北科星药业有限公司 | 一种抗禽流感卵黄抗体注射液及其用途 |
CN105727287A (zh) * | 2014-12-06 | 2016-07-06 | 郑长义 | 一种含复合亚型免疫抗体的禽流感免疫鸡蛋生产制程方法 |
CN104546715B (zh) * | 2014-12-22 | 2018-01-16 | 蓝佳堂生物医药(福建)有限公司 | 一种用于上呼吸道感染的复合抗体口腔喷剂及其制备方法 |
CN105597097A (zh) * | 2015-03-17 | 2016-05-25 | 深圳市雅臣爱己生物工程有限公司 | 抗霉菌毒素和细菌外毒素及病原体复合IgY制备方法及其制剂 |
CN108018263B (zh) * | 2017-12-22 | 2021-09-28 | 吉林冠界生物技术有限公司 | 一种重组禽流感病毒的纯化浓缩方法及其系统 |
AU2021267035A1 (en) * | 2020-05-08 | 2023-01-05 | Camas Incorporated | Reduction of viral disease transmission by avian antibodies |
CN111551745B (zh) * | 2020-05-15 | 2023-04-07 | 安徽中起生物科技有限公司 | 禽流感病毒H7N9亚型N蛋白IgY抗体检测胶体金试纸及方法 |
CN113087791B (zh) * | 2021-02-05 | 2024-04-26 | 深圳市雅臣智能生物工程有限公司 | 广谱抗变异新冠病毒IgY和复合抗体及制备方法和组合制剂 |
CN114146213A (zh) * | 2021-12-06 | 2022-03-08 | 广西博生生物科技有限公司 | 一种复合卵黄球γ蛋白的凝胶敷料及其制备方法与应用 |
CN117384295B (zh) * | 2023-12-13 | 2024-03-08 | 北京索莱宝科技有限公司 | 小鼠抗鹅IgY单克隆抗体及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1563088A (zh) * | 2004-03-19 | 2005-01-12 | 雅臣药业集团(远东)有限公司 | 一种抗流行性感冒特异性复合IgY及其新型制剂 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1384119A (zh) * | 2002-05-17 | 2002-12-11 | 重庆和润实业(集团)有限公司 | 抗禽类病毒性疫病的复合卵黄抗体及其制备和应用 |
-
2005
- 2005-10-31 CN CN2005101168462A patent/CN1958608B/zh active Active
-
2006
- 2006-02-13 WO PCT/CN2006/000212 patent/WO2007068154A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1563088A (zh) * | 2004-03-19 | 2005-01-12 | 雅臣药业集团(远东)有限公司 | 一种抗流行性感冒特异性复合IgY及其新型制剂 |
Non-Patent Citations (2)
Title |
---|
李雁冰, 李海燕, 辛晓光, 田国彬, 冯菊艳, 唐秀英, 于康震.禽流感高免球蛋白的制备及应用研究.中国兽药杂志.2002,36(9), * |
韩克光,古少鹏.精制禽流感高免卵黄抗体的研究.畜禽业.2004,(176), * |
Also Published As
Publication number | Publication date |
---|---|
WO2007068154A1 (en) | 2007-06-21 |
CN1958608A (zh) | 2007-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1958608B (zh) | 抗禽流感特异性IgY的制备方法及其制剂 | |
Taylor et al. | Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. | |
CN104602709B (zh) | 新型ha结合试剂 | |
CN112094341B (zh) | 抗新型冠状病毒的IgY中和抗体及其制备方法、制剂和应用 | |
CN113087791B (zh) | 广谱抗变异新冠病毒IgY和复合抗体及制备方法和组合制剂 | |
CN101081866A (zh) | 抗家畜和水产病原体的特异性IgY或复合IgY及其应用 | |
WO2021155639A1 (zh) | 抗SARS-CoV-2和其它冠状病毒IgY及其小分子抗体以及应用 | |
CN101879312B (zh) | 广谱型流感疫苗及其制备方法 | |
Zeigler et al. | Epitope-targeting platform for broadly protective influenza vaccines | |
CN1563088B (zh) | 一种抗流行性感冒特异性复合IgY及其制剂 | |
US20100196495A1 (en) | Delivery of flu antibodies to surfaces in contact with air | |
CN101555281A (zh) | 抗甲型H1N1流感病毒特异性IgY的制备方法及其相关制剂 | |
CN106822885A (zh) | 肺炎链球菌疫苗 | |
WO2023126009A1 (zh) | 聚合分子、包括其的单一结构和多聚结构 | |
CN101885757B (zh) | 禽流感病毒血凝素、表位肽和抗它们的单克隆抗体及其应用 | |
CN106832004B (zh) | 一种口服禽干扰素融合蛋白及其作为免疫增强剂的应用 | |
CN113248575B (zh) | 一种针对SARS-CoV-2的重组蛋白疫苗及其制备方法 | |
CN108752470A (zh) | 一种抗鲤疱疹病毒ii型orf72的卵黄抗体及其制备方法 | |
CN114470198A (zh) | 一种用于防治新冠肺炎的SARS-CoV-2卵黄中和抗体IgY喷雾剂 | |
CN104402995A (zh) | 抗流感病毒鸡卵黄抗体的制备方法及应用 | |
Howitt et al. | An outbreak of equine encephalomyelitis, eastern type, in southwestern Louisiana | |
CN100413536C (zh) | 人用狂犬病裂解疫苗 | |
WO2004101621A1 (fr) | Immunoglobuline (ig) y specifique contre le syndrome respiratoire aigu severe (sras), technique de preparation de celle-ci et combinaison de preparations contenant celle-ci | |
CN104288766A (zh) | 一种疫苗组合物及其制备方法和应用 | |
CN108484760A (zh) | 一种抗蓖麻毒素免疫球蛋白F(ab’)2及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN YACHEN BIOTECHNOLOGY TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: YACHEN PHARMACEUTICAL GROUP (THE FAR EAST) CO., LTD. Effective date: 20120229 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: HONG KONG, CHINA TO: 518000 SHENZHEN, GUANGDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120229 Address after: 518000, a bio incubator building in central high tech Zone, Shenzhen, Guangdong, 1-204, Nanshan District Applicant after: Shenzhen Yachen Biotechnology Technology Co., Ltd. Address before: Hongkong, China, Sha Tin Road, Sha Tin twelve, biotechnology two, Hongkong Institute of biotechnology, room 115, 115A Applicant before: Yachen Pharmaceutical Group (Yuandong) Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN SHANCHENG BIO-TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHENZHEN YACHEN BIOTECHNOLOGY TECHNOLOGY CO., LTD. Effective date: 20150508 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150508 Address after: 518000 Guangdong city of Shenzhen province Qianhai Shenzhen Hong Kong cooperation zone before Bay Road No. 1 building 201 room A (located in Shenzhen Qianhai business secretary Co. Ltd.) Patentee after: Shenzhen Cheng Cheng Biotechnology Co., Ltd. Address before: 518000, a bio incubator building in central high tech Zone, Shenzhen, Guangdong, 1-204, Nanshan District Patentee before: Shenzhen Yachen Biotechnology Technology Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170821 Address after: Room 9, block C, building, science and Technology Park, 1 Shenzhen Road, Longhua street, Longhua New District, Guangdong, China Patentee after: Shenzhen elegant intelligent biological engineering Co., Ltd. Address before: 518000 Guangdong city of Shenzhen province Qianhai Shenzhen Hong Kong cooperation zone before Bay Road No. 1 building 201 room A (located in Shenzhen Qianhai business secretary Co. Ltd.) Patentee before: Shenzhen Cheng Cheng Biotechnology Co., Ltd. |
|
TR01 | Transfer of patent right |